Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

DEK-NUP214 Acute Myeloid Leukemia Depends on CRM1 In Vivo

Fiorella Charles Cano, Arnold Kloos, Rucha Yeshwanta Hebalkar, Razif Gabdoulline, Thomas Fangmann, Yosef Landesman, Konstanze Döhner, Halyna R. Shcherbata, Arnold Ganser, Michael Heuser

Blood (2022) 140 (Supplement 1): 4938–4939.

https://doi.org/10.1182/blood-2022-155836

Published: 2022

Journal Articles

Sequential Administration of Selinexor then CD19 CAR-T Cells Exhibits Enhanced Efficacy in a Mouse Model of Human Non-Hodgkin's Lymphoma

Ryan Stadel, Ruifu Liu, Yosef Landesman, David Wald, Smitha Hosahalli Vasanna, Marcos J.G. de Lima

Blood (2022) 140 (Supplement 1): 7413–7414.

https://doi.org/10.1182/blood-2022-164443

Published: 2022

Journal Articles

Dual Targeting PAK4 and NAMPT As a Novel Therapeutic Approach for Aggressive Non-Hodgkin's Lymphoma

Suresh Kumar Balasubramanian, Husain Khan, Md. Hafiz Uddin, Amro Aboukameel, Yiwei Li, Jeffrey A. Zonder, William T. Senapedis, Jr., Erkan Baloglu, Ramzi Mohammad, Jatin J. Shah, Yosef Landesman, Sharon Shacham, Michael G. Kauffman, Asfar Sohail Azmi

Blood (2021) 138 (Supplement 1): 683.

https://doi.org/10.1182/blood-2021-145615

Published: 2021

Journal Articles

Selinexor Enhances NK Cell Activation Against Lymphoma Cells Via Downregulation of HLA-E

Jack Fisher, Christopher J. Walker, Peter Johnson, Mark S Cragg, Francesco Forconi, Yosef Landesman, Salim I Khakoo, Matthew D Blunt

Blood (2021) 138 (Supplement 1): 2411.

https://doi.org/10.1182/blood-2021-144836

Published: 2021

Journal Articles

Transcriptomic Correlates of Response to Selinexor in Multiple Myeloma Reveal a Predictive Signature

Paula Restrepo, Sherry Bhalla, Adolfo Aleman, Violetta Leshchenko, Sarita Agte, Yogita Ghodke-Puranik, Joy Jiang, Mark M. Stevens, Deepu Madduri, Joshua Richter, Shambavi Richard, Ajai Chari, Hearn Jay Cho, Sundar Jagannath, Christopher J Walker, Yosef Landesman, Alessandro Lagana, Samir Parekh

Blood (2021) 138 (Supplement 1): 457.

https://doi.org/10.1182/blood-2021-150522

Published: 2021

Journal Articles

Characterization of Synergistic Selinexor Combinations of Dexamethasone, Pomalidomide, Elotuzumab and Daratumumab in Primary MM Samples Ex Vivo

Kenneth H. Shain, MD PhD, Rafael Renatino-Canevarolo, PhD, Mark B. Meads, PhD, Praneeth Reddy Sudalagunta, PhD, Maria D Coelho Siqueira Silva, MSc, Christopher Cubitt, Gabriel De Avila, BS, Raghunandan Reddy Alugubelli, Amit Kulkarni, PhD, Qi Zhang, PhD, Oliver Hampton, Constantine Logothetis, MD, Christian Argueta, PhD, Yosef Landesman, PhD, Ariosto Siqueira Silva, PhD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-140485

Published: 2020

Journal Articles

CRISPR/Cas9 Chemogenetic Profiling Identifies Candidate Biomarker Genes That Modulate Sensitivity to Selinexor

Bert Kwanten, MSc, Yosef Landesman, PhD, Dirk Daelemans

Blood (2020) 136 (Supplement 1): 14.

https://doi.org/10.1182/blood-2020-141785

Published: 2020

Journal Articles

A Six-Protein Activity Signature Defines Favorable Response to Selinexor Treatment for Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Christopher J. Walker, PhD, Yao Shen, PhD, Mariano Alvarez, PhD, Hua Chang, PhD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Andrea Califano, Dr, Yosef Landesman, PhD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-142004

Published: 2020

Journal Articles

Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston Study

Shambavi Richard, MD, Ajai Chari, MD, Sosana Delimpasi, MD, Maryana Simonova, MD, Ivan Spicka, MD PhD, Ludek Pour, MD, Irina Kryachok, MD, Meletios A Dimopoulos, Halyna Pylypenko, MD, Holger W Auner, MD PhD, Xavier Leleu, MD, Vadim A Doronin, MD, Ganna Usenko, MD, Roman Hajek, MD, Reuben Benjamin, FRCPath, MRCP, MBBS, PhD, Tuphan Kanti Dolai, MBBS, MD DNB, DM, Dinesh Kumar Sinha, MD, Christopher P. Venner, MD, Mamta Garg, MD FRCP, FRCPath, Don A. Stevens, MD, Hang Quach, MDFRACP,FRCPA,MBBS, Sundar Jagannath, MD, Philippe Moreau, MD, Moshe Y. Levy, MD, Ashraf Z. Badros, MD, Larry D. Anderson, Jr., MD PhD, Nizar J. Bahlis, MD, Thierry Facon, MD, Maria-Victoria Mateos, MD PhD, Michele Cavo, Hua Chang, PhD, Yosef Landesman, PhD, Anita A. Joshi, Yi Chai, Melina Arazy, MD, Jatin Shah, MD, Sharon Shacham, PhD MBA, Michael G Kauffman, MD PhD, Sebastian Grosicki, MD PhD, Paul G. Richardson, MD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-137154

Published: 2020

Journal Articles

A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple Myeloma

Alessandro Lagana, PhD, Sherry Bhalla, Adolfo Aleman, Anna Huo-Chang Mei, MS, Violetta Leshchenko, PhD, Yosef Landesman, PhD, David Melnekoff, BS,MS, Itai Beno, PhD, Deepu Madduri, MD, Joshua R Richter, MD, Ajai Chari, MD, Hearn Jay Cho, MD PhD, Sundar Jagannath, MD, Joel Dudley, PhD, Samir Parekh, MD

Blood (2019) 134 (Supplement_1): 3101.

https://doi.org/10.1182/blood-2019-130753

Published: 2019

Journal Articles

E2F1 Is a Biomarker of Selinexor Resistance in Relapsed/Refractory Multiple Myeloma Patients

Alessandro Lagana, PhD, Seongjee Park, Donna Edwards, Violetta Leshchenko, PhD, Marsha Crochiere, Yosef Landesman, PhD, David Melnekoff, BS,MS, Itai Beno, PhD, Deepak Perumal, PhD, Deepu Madduri, MD, Joshua Richter, Ajai Chari, MD, Hearn Jay Cho, MD, Bart Barlogie, MD PhD, Sundar Jagannath, MD, Joel Dudley, PhD, Samir Parekh, MD

Blood (2018) 132 (Supplement 1): 3216.

https://doi.org/10.1182/blood-2018-99-116500

Published: 2018

Journal Articles

The Mechanisms By Which Mutant-NPM1 Uncouples Differentiation from Proliferation Are Reversed By Several Drugs, Enabling Rational Multi-Component Non-Cytotoxic Differentiation Therapy

Xiaorong Gu, PhD, Quteba Ebrahem, MD, Reda Z. Mahfouz, MD PhD, Metis Hasipek, PhD, Francis Enane, PhD, Tomas Radivoyevitch, Nicolas Rapin, PhDMSc, Bartlomiej P. Przychodzen, MSc, Ramesh Balusu, PhD, Claudiu V Cotta, David Wald, MD PhD, Zhenbo Hu, MD PhD, Yosef Landesman, PhD, Maria Paola Martelli, MD PhD, Brunangelo Falini, MD, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, PhD MD FACP, Babal K Jha, PhD, Yogenthiran Saunthararajah, MD

Blood (2017) 130 (Supplement 1): 878.

https://doi.org/10.1182/blood.V130.Suppl_1.878.878

Published: 2017

Journal Articles

XPO1 Inhibitor Selinexor Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma Via Nuclear Retention of IκB

Y. Lynn Wang, MD PhD, Mei Ming, PhD, Bingqing Xie, Madina Sukhanova, Weige Wang, MD, Sabah Kadri, PhD, Shruti Sharma, Jimmy Lee, Sharon Shacham, PhD MBA, Yosef Landesman, PhD, Natalia Maltsev, Pin Lu, PhD

Blood (2017) 130 (Supplement 1): 3837.

https://doi.org/10.1182/blood.V130.Suppl_1.3837.3837

Published: 2017

Journal Articles

Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis

Kellie R. Machlus, Stephen K. Wu, Prakrith Vijey, Thomas S. Soussou, Zhi-Jian Liu, Eran Shacham, T. J. Unger, Trinayan Kashyap, Boris Klebanov, Martha Sola-Visner, Marsha Crochiere, Joseph E. Italiano, Jr, Yosef Landesman

Blood (2017) 130 (9): 1132–1143.

https://doi.org/10.1182/blood-2016-11-752840

Published: 2017

Includes: Supplemental data

Journal Articles

Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma

Blood (2017) 129 (16): 2233–2245.

https://doi.org/10.1182/blood-2016-06-724831

Published: 2017

Includes: Supplemental data

Journal Articles

XPO1 Target Occupancy Measurements Using Fluorescence Cross Correlation Spectroscopy Support the Selinexor Recommended Phase 2 Dose

Marsha L. Crochiere, PhD, Stefan Hannus, PhD, Kerrin Hansen, Frank Becker, PhD, Erkan Baloglu, PhD, Michael Kauffman, MD PhD, Yosef Landesman, PhD

Blood (2016) 128 (22): 1563.

https://doi.org/10.1182/blood.V128.22.1563.1563

Published: 2016

Journal Articles

Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells, Also Overcoming Intrinsic and Stromal Cells-Mediated Fludarabine Resistance

Maria Todaro, PhD, Valentina Griggio, Ms, Candida Vitale, MD, Chiara Salvetti, MD, Chiara Riganti, MD, Mario Boccadoro, MD, Yosef Landesman, PhD, Marta Coscia, MD PhD

Blood (2016) 128 (22): 3210.

https://doi.org/10.1182/blood.V128.22.3210.3210

Published: 2016

Journal Articles

Combination Therapy with Bortezomib or Carfilzomib and Selinexor Induces Nuclear Localization of Ikbα and Overcomes Acquired Proteasome Inhibitor Resistance in Human Multiple Myeloma

Joel G Turner, PhD, Trinayan Kashyap, MS, Jana L Dawson, BS, Juan A Gomez, BS, Alexis Bauer, BS, Steven Grant, MD, Yun Dai, PhD, Kenneth H. Shain, MD PhD, Mark B Meads, PhD, Yosef Landesman, PhD, Daniel M Sullivan, MD

Blood (2016) 128 (22): 3299.

https://doi.org/10.1182/blood.V128.22.3299.3299

Published: 2016

Journal Articles

Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T Cell Effector Function in Mice: Implications for Combination with Immunotherapy

Paul M Tyler, Mariah M Servos, Boris Klebanov, Trinayan Kashyap, MS, Sharon Shacham, PhD MBA, Yosef Landesman, PhD, Michael Dougan, Stephanie K Dougan

Blood (2016) 128 (22): 2525.

https://doi.org/10.1182/blood.V128.22.2525.2525

Published: 2016

Journal Articles

Efficacy of Selinexor Is Dependent on IκB-α Expression and NF-Kb Deactivation in Multiple Myeloma Cells

Trinayan Kashyap, MS, Boris Klebanov, MA, MS, Christian Argueta, PhD, Margaret S. Lee, PhD, Sharon Shacham, PhD MBA, Michael Kauffman, MD PhD, Yosef Landesman, PhD, William Senapedis, PhD

Blood (2016) 128 (22): 5660.

https://doi.org/10.1182/blood.V128.22.5660.5660

Published: 2016

NARROW

DEK-NUP214 Acute Myeloid Leukemia Depends on CRM1 In Vivo

Sequential Administration of Selinexor then CD19 CAR-T Cells Exhibits Enhanced Efficacy in a Mouse Model of Human Non-Hodgkin's Lymphoma

Dual Targeting PAK4 and NAMPT As a Novel Therapeutic Approach for Aggressive Non-Hodgkin's Lymphoma

Selinexor Enhances NK Cell Activation Against Lymphoma Cells Via Downregulation of HLA-E

Transcriptomic Correlates of Response to Selinexor in Multiple Myeloma Reveal a Predictive Signature

Characterization of Synergistic Selinexor Combinations of Dexamethasone, Pomalidomide, Elotuzumab and Daratumumab in Primary MM Samples Ex Vivo

CRISPR/Cas9 Chemogenetic Profiling Identifies Candidate Biomarker Genes That Modulate Sensitivity to Selinexor

A Six-Protein Activity Signature Defines Favorable Response to Selinexor Treatment for Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston Study

A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple Myeloma

E2F1 Is a Biomarker of Selinexor Resistance in Relapsed/Refractory Multiple Myeloma Patients

The Mechanisms By Which Mutant-NPM1 Uncouples Differentiation from Proliferation Are Reversed By Several Drugs, Enabling Rational Multi-Component Non-Cytotoxic Differentiation Therapy

XPO1 Inhibitor Selinexor Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma Via Nuclear Retention of IκB

Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis

Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma

XPO1 Target Occupancy Measurements Using Fluorescence Cross Correlation Spectroscopy Support the Selinexor Recommended Phase 2 Dose

Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells, Also Overcoming Intrinsic and Stromal Cells-Mediated Fludarabine Resistance

Combination Therapy with Bortezomib or Carfilzomib and Selinexor Induces Nuclear Localization of Ikbα and Overcomes Acquired Proteasome Inhibitor Resistance in Human Multiple Myeloma

Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T Cell Effector Function in Mice: Implications for Combination with Immunotherapy

Efficacy of Selinexor Is Dependent on IκB-α Expression and NF-Kb Deactivation in Multiple Myeloma Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only